Inovio Pharmaceuticals Inc expected to post a loss of 61 cents a share - Earnings Preview

Inovio Pharmaceuticals

04/08/2025 12:03

Inovio Pharmaceuticals Inc INO.OQ INO.O is expected to  show a fall in quarterly revenue when it reports  results on August 6 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Inovio Pharmaceuticals Inc is for a loss of 61 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Inovio Pharmaceuticals Inc is $7.50, about 80.9% above its last closing price of $1.43

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.75
-0.74
-0.41
Beat
44.4
Dec. 31 2025
-0.79
-0.84
-0.60
Beat
28.3
Sep. 30 2024
-1.14
-1.15
-0.89
Beat
22.6​
Jun. 30 2024
-1.12
-1.10
-1.19
Missed
-8
​​Mar. 31 2024
-1.01
-1.00
-1.31
Missed
-30.6
Dec. 31 2023
-1.42
-1.27
-1.12
Beat
11.6​
Sep. 30 2023
-1.50
-1.52
-1.56
Missed
-2.6
Jun. 30 2023
-1.81
-1.74
-1.56
Beat
10.3

This summary was machine generated August 4 at 11:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)